<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ophthalmol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Ophthalmol Ther</journal-id><journal-title-group><journal-title>Ophthalmology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8245</issn><issn pub-type="epub">2193-6528</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25794551</article-id><article-id pub-id-type="pmc">4470981</article-id><article-id pub-id-type="publisher-id">30</article-id><article-id pub-id-type="doi">10.1007/s40123-015-0030-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Reply to Hall J: &#x0201c;Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population&#x0201d;</article-title><subtitle>Virender S. Sangwan, P. Andrew Pearson, Hemanth Paul, Timothy L. Comstock</subtitle></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Scassellati Sforzolini</surname><given-names>Baldo</given-names></name><address><email>Baldo.Sforzolini@bausch.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Eye Care, Valeant Pharmaceuticals, Bridgewater, NJ USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><volume>4</volume><issue>1</issue><fpage>67</fpage><lpage>68</lpage><history><date date-type="received"><day>2</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>I read with interest Dr. Hall&#x02019;s letter. While the article titled &#x0201c;Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis (NIPU): 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population&#x0201d; [<xref ref-type="bibr" rid="CR2">1</xref>] clearly identified Retisert<sup>&#x000ae;</sup> (fluocinolone acetonide intravitreal implant) 0.59&#x000a0;mg as the marketed product used in the study, we appreciate Dr. Hall&#x02019;s concern that there may be some potential confusion regarding the features of Retisert compared with those of Iluvien<sup>&#x000ae;</sup> (fluocinolone acetonide intravitreal implant) 0.19&#x000a0;mg, as they both contain fluocinolone acetonide as the active ingredient, and we are in support of a letter outlining their differences [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>However, we disagree with the promotional implication that Iluvien is an &#x0201c;improvement&#x0201d; over Retisert as there are no head-to-head clinical trials comparing these two products to merit that claim. Indeed, in addition to the approval for treatment of chronic non-infectious posterior uveitis, clinical studies have shown Retisert to be effective in reducing diabetic macular edema (DME) and improving visual acuity in patients with DME [<xref ref-type="bibr" rid="CR3">3</xref>]. Retisert has also shown efficacy in the management of macular edema secondary to retinal vein occlusion in small studies [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. However, as Dr. Hall correctly stated, Retisert is not approved either in the US or in Europe for these latter indications.</p><p>Baldo Scassellati Sforzolini, MD, PhD, MBA</p><p>Vice President Development, Eye Care, Valeant Pharmaceuticals</p><p>Bridgewater, NJ, USA</p><p>Baldo.Sforzolini@bausch.com</p></body><back><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Sangwan VS, Pearson PA, Paul H, Comstock TL. Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Opthalmol Ther. doi:10.1007/s40123-014-0027-6.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Hall J. Comment on: Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Ophthalmol Ther. 2014. doi:10.1007/s40123-015-0029-z.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>PA</given-names></name><name><surname>Comstock</surname><given-names>TL</given-names></name><name><surname>Ip</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial</article-title><source>Ophthalmology</source><year>2011</year><volume>118</volume><issue>8</issue><fpage>1580</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2011.02.048</pub-id><pub-id pub-id-type="pmid">21813090</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramchandran</surname><given-names>RS</given-names></name><name><surname>Fekrat</surname><given-names>S</given-names></name><name><surname>Stinnett</surname><given-names>SS</given-names></name><name><surname>Jaffe</surname><given-names>GJ</given-names></name></person-group><article-title>Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results</article-title><source>Am J Ophthalmol</source><year>2008</year><volume>146</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2008.03.025</pub-id><pub-id pub-id-type="pmid">18533125</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>N</given-names></name><name><surname>Stinnett</surname><given-names>SS</given-names></name><name><surname>Jaffe</surname><given-names>GJ</given-names></name></person-group><article-title>Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results</article-title><source>Ophthalmology</source><year>2012</year><volume>119</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2011.06.019</pub-id><pub-id pub-id-type="pmid">21924503</pub-id></element-citation></ref></ref-list></back></article>